유럽 연합 - 크로아티아어 - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastična sredstva - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

유럽 연합 - 크로아티아어 - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol - astma - lijekovi za opstruktivne plućne bolesti dišnih putova, - budesonid / formoterol teva pharma b. je indiciran u odrasloj dobi od 18 godina i stariji. asthmabudesonide/Формотерола tewa pharma b. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists. in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.

유럽 연합 - 크로아티아어 - EMA (European Medicines Agency)

taw pharma (ireland) limited - klopidogrel hidroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotska sredstva - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

크로아티아 - 크로아티아어 - HALMED (Agencija za lijekove i medicinske proizvode)

sandoz d.o.o., maksimirska 120, zagreb - buprenorphinum - transdermalni flaster - 10 mikrograma/h - urbroj: svaki transdermalni flaster sadrži 10 mg buprenorfina na 12,5 cm2, otpuštajući 10 mikrograma buprenorfina na sat

크로아티아 - 크로아티아어 - HALMED (Agencija za lijekove i medicinske proizvode)

sandoz d.o.o., maksimirska 120, zagreb - buprenorphinum - transdermalni flaster - 15 mikrograma/h - urbroj: svaki transdermalni flaster sadrži 15 mg buprenorfina na 18,75 cm2, otpuštajući 15 mikrograma buprenorfina na sat

크로아티아 - 크로아티아어 - HALMED (Agencija za lijekove i medicinske proizvode)

sandoz d.o.o., maksimirska 120, zagreb - buprenorphinum - transdermalni flaster - 20 mikrograma/h - urbroj: svaki transdermalni flaster sadrži 20 mg buprenorfina na 25 cm2, otpuštajući 20 mikrograma buprenorfina na sat

크로아티아 - 크로아티아어 - HALMED (Agencija za lijekove i medicinske proizvode)

sandoz d.o.o., maksimirska 120, zagreb - buprenorphinum - transdermalni flaster - 5 mikrograma/h - urbroj: svaki transdermalni flaster sadrži 5 mg buprenorfina na 6,25 cm2, otpuštajući 5 mikrograma buprenorfina na sat

크로아티아 - 크로아티아어 - HALMED (Agencija za lijekove i medicinske proizvode)

johnson & johnson s.e. d.o.o., oreškovićeva 6h, zagreb, hrvatska - fentanil - transdermalni flaster - 16,8 mg (100 mikrograma/sat) - urbroj: jedan transdermalni flaster sadrži 16,8 mg fentanila. površina flastera je 42,0 cm2 (oslobađanje fentanila 100 mikrograma/sat što predstavlja 2,4 mg/24 sata)

크로아티아 - 크로아티아어 - HALMED (Agencija za lijekove i medicinske proizvode)

johnson & johnson s.e. d.o.o., oreškovićeva 6h, zagreb, hrvatska - fentanil - transdermalni flaster - 2,1 mg (12,5 mikrograma/sat) - urbroj: jedan transdermalni flaster (5,25 cm2) sadrži 2,1 mg fentanila (brzina otpuštanja je 12,5 µg/h što odgovara 0,3 mg/24 h)

크로아티아 - 크로아티아어 - HALMED (Agencija za lijekove i medicinske proizvode)

johnson & johnson s.e. d.o.o., oreškovićeva 6h, zagreb, hrvatska - fentanil - transdermalni flaster - 4,2 mg (25 mikrograma/sat) - urbroj: jedan transdermalni flaster (10,5 cm2) sadrži 4,2 mg fentanila (brzina otpuštanja je 25 µg/h što odgovara 0,6 mg/24 h)